Chang JY - Search Results

1

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Y, Hsieh RK, Chang JY, Shan YS, Chao Y, Chen LT; Taiwan Cooperative Oncology Group. Chen JS, et al. Among authors: chang jy, chang ic. Ann Oncol. 2015 May;26(5):943-949. doi: 10.1093/annonc/mdv035. Epub 2015 Jan 28. Ann Oncol. 2015. PMID: 25632066 Free article. Clinical Trial.

2

Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?

Cheng AL, Chen YC, Wang CH, Su IJ, Hsieh HC, Chang JY, Hwang WS, Su WC, Liu TW, Tien HF, et al. Cheng AL, et al. Among authors: chang jy. J Clin Oncol. 1989 Jun;7(6):725-31. doi: 10.1200/JCO.1989.7.6.725. J Clin Oncol. 1989. PMID: 2654330

3

Weekly CAF chemotherapy for advanced breast cancer patients.

Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM, Hsieh RK, Tsao CJ, Chen LT, Law CK, Cheng AL, Fan SF, Tzeng CH, Chiou TJ, Whang-Peng J. Hwang WS, et al. Among authors: chang jy. Oncology. 1997 Jul-Aug;54(4):293-7. doi: 10.1159/000227706. Oncology. 1997. PMID: 9216853 Clinical Trial.

4

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK, Cheng AL. Chao Y, et al. Among authors: chang cs, chang jy, chang cj. Br J Cancer. 2004 Aug 2;91(3):453-8. doi: 10.1038/sj.bjc.6601985. Br J Cancer. 2004. PMID: 15226770 Free PMC article. Clinical Trial.

5

Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.

Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Wang HM, et al. Among authors: chang jy. Ann Oncol. 2013 May;24(5):1312-9. doi: 10.1093/annonc/mds616. Epub 2013 Jan 8. Ann Oncol. 2013. PMID: 23300016 Free PMC article.

6

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Welsh JW, et al. Among authors: chang jy. J Clin Oncol. 2013 Mar 1;31(7):895-902. doi: 10.1200/JCO.2011.40.1174. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341526 Free PMC article. Clinical Trial.

7

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.

Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT. Chang TC, et al. Among authors: chang jy. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86. doi: 10.1007/s00280-014-2671-x. Epub 2015 Jan 11. Cancer Chemother Pharmacol. 2015. PMID: 25577133 Free PMC article. Clinical Trial.

8

Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.

Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Nguyen QN, et al. Among authors: chang jy. Radiother Oncol. 2015 Jun;115(3):367-72. doi: 10.1016/j.radonc.2015.05.014. Epub 2015 May 28. Radiother Oncol. 2015. PMID: 26028228 Free PMC article.

9

Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer.

Chao TY, Hwang WS, Yang MJ, Chang JY, Wang CC, Hseuh EJ, Huang SH, Chen WC. Chao TY, et al. Among authors: chang jy. Zhonghua Yi Xue Za Zhi (Taipei). 1995 Oct;56(4):232-8. Zhonghua Yi Xue Za Zhi (Taipei). 1995. PMID: 8548664 Clinical Trial.

10

A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.

Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. Liao Z, et al. Among authors: chang jy. Clin Cancer Res. 2005 May 1;11(9):3342-8. doi: 10.1158/1078-0432.CCR-04-1741. Clin Cancer Res. 2005. PMID: 15867233 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,748 results

Search Page